A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy
Open accessThe DOI matches its Crossref record; 45 of the 48 references it cites were found in a registry or an index.
Abstract
p53 and INK4a/ARF mutations promote tumorigenesis and drug resistance, in part, by disabling apoptosis. We show that primary murine lymphomas also respond to chemotherapy by engaging a senescence program controlled by p53 and p16(INK4a). Hence, tumors with p53 or INK4a/ARF mutations-but not those lacking ARF alone-respond poorly to cyclophosphamide therapy in vivo. Moreover, tumors harboring a Bcl2-mediated apoptotic block undergo a drug-induced cytostasis involving the accumulation of p53, p16(INK4a), and senescence markers, and typically acquire p53 or INK4a mutations upon progression to a terminal stage. Finally, mice bearing tumors capable of drug-induced senescence have a much better prognosis following chemotherapy than those harboring tumors with senescence defects. Therefore, cellular senescence contributes to treatment outcome in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Indeed, p16Ink4a is often used as a prognostic marker in some cancers, such as breast, colon, or head and neck cancer; however, in cancers, p16 rarely induces cell cycle arrest151.”
From Guidelines for minimal information on cellular senescence experimentation in vivo (2024) · cites this paper as [151]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, as cancer progresses, features of senescence are lost or mutated in cancer cells, including the expression levels of the tumor suppressor p53 and CDKN2A/CDKN2B loci gene products, p16Ink4a, p14/p19ARF, and p15INK4b.”
From Guidelines for minimal information on cellular senescence experimentation in vivo (2024) · cites this paper as [151]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Irradiation, chemotherapy and some targeted anti-cancer drugs, including aurora kinase inhibitors, all induce senescence 40,42.”
From Cardiac glycosides are broad-spectrum senolytics (2019) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therapy-induced senescence determines the response to chemo- and radiotherapy 40”
From Cardiac glycosides are broad-spectrum senolytics (2019) · cites this paper as [40]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The serial cultivation of human diploid cell strains
Hayflick, L., & Moorhead, P. S. (1961) · Experimental Cell Research · doi:10.1016/0014-4827(61)90192-6 · Cited by 8,508 · cited 1×
“Hence, loss of either p53 or INK4a genes disabled premature senescence provoked by CTX.cative aging of human fibroblasts in culture (Hayflick and Moorhead, 1961), is considered permanent and is These findings demonstrate that the outcome of cancer therapy can be linked to a drug-inducible…”
BackgroundA biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
The limited in vitro lifetime of human diploid cell strains
Hayflick, L. (1965) · Experimental Cell Research · doi:10.1016/0014-4827(65)90211-9 · Cited by 5,876
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 2×
“Although CTX is not subjectvated oncogenes, oxidative stress, radiation, and certain chemotherapeutic drugs (Chang et al., 1999; Di Leo- to resistance mechanisms involving enhanced drug ef- flux, many human tumors respond poorly or becomenardo et al., 1994; Serrano et al., 1997).”
BackgroundSelf-citationParticipation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
Self-citationRequirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
Self-citationThe c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Cited by
Oxidative stress, inflammation, and cancer: How are they linked?
Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.09.006 · Cited by 5,441
Cellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441
Aging, Cellular Senescence, and Cancer
Campisi, J. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183653 · Cited by 2,954
Cancer and Radiation Therapy: Current Advances and Future Directions
Baskar, R., Lee, K. A., Yeo, R., & Yeoh, K.-W. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.3635 · Cited by 2,880
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell · doi:10.1016/s0092-8674(03)00401-x · Cited by 2,278
Self-citation
Metadata
- Authors
- Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., & Lowe, S. W.
- Affiliations
- Cold Spring Harbor Laboratory (US)
- AntiCancer (United States) (US)
- Corresponding author
- Lowe, Scott W.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2002-05
- Volume
- 109
- Issue
- 3
- Pages
- 335-346
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W1990161819
- Semantic Scholar
- 08b2333193ea779da8664dbbbcf59bd814134f9c
- Cited by
- 1,050
- References
- 48
- Citations by year
- 2026: 15 · 2025: 33 · 2024: 25 · 2023: 37 · 2022: 32 · 2021: 34 · 2020: 37 · 2019: 42 · 2018: 34 · 2017: 34 · 2016: 51 · 2015: 40 · 2014: 42 · 2013: 56 · 2012: 50
- FWCI
- 37.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4095 d)
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- Funders
- National Institutes of Health (1r43ca089779-01)
- National Cancer Institute (CA-87497, P01CA087497, CA89779, P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Keywords
- cellular senescence, p53, p16INK4a, ARF, lymphoma, cyclophosphamide, chemotherapy response, drug resistance, Bcl-2, apoptosis, tumor progression, prognosis
- MeSH terms
- Animals, Cell Survival, Cyclophosphamide, Mice, Mutant Strains, Mutation, Prognosis, Proto-Oncogene Proteins, Tumor Cells, Cultured, Biomarkers, Tumor Suppressor Protein p53, Lymphoma, B-Cell, Cellular Senescence, Apoptosis, Mice, Knockout, Antineoplastic Agents, Alkylating, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-bcl-2, Cyclin-Dependent Kinase Inhibitor p16, Tumor Suppressor Protein p14ARF, Ubiquitin-Protein Ligases, Proto-Oncogene Proteins c-cbl, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy. https://app.cochat.ai/papers/10.1016/s0092-8674(02)00734-1
- The paper
- Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002). A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy. Cell. https://doi.org/10.1016/s0092-8674(02)00734-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.